Abstract − This study was undertaken to investigate whether honokiol could enhance the pentobarbitalinduced sleeping behaviors through γ-aminobutyric acid (GABA) receptor Cl -channel activation. Thirty minutes after the oral administration of honokiol, mice were received sodium pentobarbital (42 mg/kg, i.p.). The time elapsed from pentobarbital injection to the loss of the righting reflex was taken as sleeping latency. The time elapsed between the loss and voluntary recovery of the righting reflex was considered as the total sleeping time. Western blot technique and Cl -sensitive fluorescence probe were used to detect the expression of GABA A receptor subunits and Cl -influx in the primary cultured cerebellar granule cells. Honokiol (0.1 and 0.2 mg/kg) prolonged the sleeping time induced by pentobarbital (42 mg/kg) in a dosage-dependent manner. Honokiol (20 and 50 µM) increased Cl -influx in primary cultured cerebellar granule cells, and selectively increased the GABA A receptor α-subunit expression, but had no effect on the abundance of β or γ-subunits. Chronic treatment with 20 µM honokiol in primary cultured cerebellar neurons did not affect the abundance of GAD65/67. The results suggested that honokiol could potentiate pentobarbital-induced sleeping through GABA A receptor Cl -channel activation.
INTRODUCTION
Honokiol (C 18 H 18 O 2 , molecular weight = 266.33; Figure  1 ) is one of biphenolic compounds isolated from the bark of the root and stem of various Magnolia species (Clark et al., 1981; Martínez et al., 2006) , which have been used for the treatment of a variety of inflammatory and neuronal diseases. The biphenolic compounds were initially thought of as the major active compounds of the plants. Honokiol has several pharmacological benefits, including antimicrobial (Clark et al., 1981) , anti-inflammatory (Liou et al., 2003a; Lee et al., 2005; Chiang et al., 2006) , antioxidative (Liou et al., 2003b; Sheu et al., 2008) , anxiolytic (Kuribara et al., 1998; Kuribara et al., 2000) , antiangiogenic (Liou et al., 2003c; Li et al., 2008) , and antineoplastic effects (Battle et al., 2005; Sheu et al., 2007) .
γ-Aminobutyric acid (GABA) is the major inhibitory neurotransmitter in the central nervous system (CNS), where it mediates fast inhibition by activating synaptic ionotropic γ-aminobutyric acid type A (GABA A ) receptors. GABA is synthesized by a specific enzyme, glutamic acid decarboxylase (GAD) from glutamate. Structural and physiological heterogeneity of the pentameric composition of the GABA A receptors, as well as the different distribution of its receptor subtypes in specific brain areas, provides an important basis for the development of therapeutic drugs. It was reported that the GABAergic system of anterior and hypothalamic neurons plays an important role in sleep (Gottesmann, 2002) . A variety of modulators of GABA-transmission, including neurosteroids, benzodiazepines, barbiturates and GABA agonists were investigated in in vitro and in vivo models. Enhancement of GABAergic neuronal inhibition underlies the therapeutic action in the treatment of generalized anxiety disorders, panic anxiety, sleep disturbances and epilepsy including status epilepticus (Rudolph and Möhler, 2006) .
In this study, we investigated whether honokiol could enhance the pentobarbital-induced sleeping behaviors through GABA A receptors Cl -channel activation.
MATERIALS AND METHODS

Isolation of honokiol
Honokiol (purity, ≥ 95%) was isolated from cortex of Magnolia officinalis. Grinded cortex of Magnolia officinalis (100 g) was extracted with CHCl 3 /MeOH (5:1, 400 ml) at 70 o C for 5 h. After filtration, the extract (12 g) was concentrated to dryness in vacuole. The dried extract was applied to a silica gel column and eluted with CHCl 3 to give crude honokiol fraction. After evaporation, the crude honokiol fraction (3.0 g) was further purified on a silica gel column using a solvent mixture of hexane and EtOAc (4:1) to yield honokiol (1.3 g). The purity (99.3%) was determined by HPLC (A Waters 600 controller, 717 plus autosampler, 2996 photodiode array detector) on C18 column (Luna, 5 mm, 250×4.6 mm, Phenomenex, USA) using mobile phase of 80% methanol (flow rate, 0.5ml/min; detection wavelength, 280 nm). The chemical structure was shown in Figure 1 .
Reagents and chemicals
Pentobarbital sodium was obtained from Hanlim Pharm. Co., Ltd. (Korea). Fetal bovine serum and Dulbecco's Modified Eagle's Medium (DMEM) were purchased from GIBCO (Grand Island, USA). The N-(ethoxycarbonylmethyl)-6-methoxyquinolinium bromide (MQAE) was obtained from Invitrogen (USA). The specific rabbit polyclonal antibodies against GABA A receptor subunits or GAD65/67 and the corresponding conjugated anti-rabbit immunoglobulin G-horseradish peroxidase were obtained from Santa Cruz Biotechnology Inc. (USA). The ECL Western blotting detection system was obtained from Roche Diagnostics (USA). All the other chemicals used in these experiments were obtained from Sigma (St Louis, MO, USA).
Animals
The animals used were ICR male mice (Samtako, Korea), weighing 22-25 g, in groups of 10-12. The mice were housed in acrylic cages with water and food available ad libitum under an artificial 12-h light/dark cycle (light on at 7:00 am) and at a constant temperature (22±2 o C). To ensure adaptation to the new environment, the mice were kept in the departmental holding room for 1 week before testing. In the case of oral administration, the mice were fasted for 24 h before testing. All the experiments were conducted in accordance with the National Institute of Toxicological Research on the Korea Food and Drug Administration guidelines for the care and use of laboratory animals.
Pentobarbital-induced sleeping
Pentobarbital sodium was diluted in 0.9% physiological saline and administered to each mouse intraperitoneally (i.p.) to induce sleep. Test samples suspended in 1% CMC in physiological saline were administered orally (p.o.) to mice (0.1 ml/10 g). All experiments were carried out between 1:00 and 5:00 pm. Animals were fasted for 24 h prior to the experiment. Pentobarbital was given to animals placed in a box 30 min after the oral administration of honokiol. Those animals that stopped moving in the box within 15 min after pentobarbital injection were immediately transferred to another box. Those individuals that stayed immobile for more than 3 min were judged to be asleep. The time that elapsed from receiving pentobarbital until an animal, positioned delicately on its back, lost its righting reflex represented the latency to onset of sleep. The animals were observed constantly, and the time of awakening, characterized by righting of the animal, was noted. The sleeping time was defined as the time taken for the animal to regain spontaneous movements after having been transferred to the second box. Animals that failed to fall asleep within 15 min after pentobarbital administration were excluded from the experiments (Wolfman et al., 1996; Darias et al., 1998) .
Primary culture of cerebellar neurons
Primary cultures of cerebellar neurons enriched in granule cells were prepared from cerebella of 8 d old SD rats as previous report (Houston et al., 2006; Han et al., . After culture for 8 d, these cells express functional GABA A receptors, with an expression pattern similar to that apparent in the cerebellum during postnatal development but different from that observed in the adult rat cerebellum. Briefly, cells were plated (1×10 6 cells per 0.2 ml) in 96 microplates or (2×10 6 per 2.0 ml) in 60-mm dishes that had been coated with poly-D-lysine (10 mg/ ml) (Sigma, USA). The cells were cultured in DMEM supplemented with 10% heat-inactivated fetal bovine serum, 2 mM glutamine, gentamicin (100 mg/ml), antibiotic-antimycotic solution (100 unit/ml) and 25 mM KCl. Cytosine arabinofuranoside (10 mM final concentration) was added to cultures 18-24 h after plating to inhibit the proliferation of non-neuronal cells.
Measurement of intracellular chloride influx
The intracellular chloride ion (Cl -) concentration of cerebellar granule cells was estimated using the Cl -sensitive fluorescence probe MQAE, according to the method of West and Molloy with a slight modification (West and Molloy, 1996) . The buffer (pH 7.4) used contained the following: 2.4 mM HPO 4 2-, 0.6 mM H 2 PO 4 -, 10 mM HEPES, 10 mM D-glucose and 1 mM MgSO 4 . A variety of MQAEloading conditions were assessed. The cells were incubated overnight in a medium containing 10 mM MQAE. After loading, the cells were washed three times in the relevant Cl -containing buffer. Then, the wash buffer was replaced with the buffer with or without the compounds or control. Repetitive fluorescence measurements were initiated immediately using a FLUOstar (excitation wavelength: 320 nm; emission wavelength: 460 nm; BMG LabTechnology, Germany). The data was presented as the relative fluorescence F 0 /F, where F 0 was the fluorescence without Cl -ions and F was the fluorescence as a function of time. The F 0 /F values were directly proportional to [Cl - ] i .
Expression of GABA A receptor subunits and GAD65/67
At the eighth day of culture, the treatment of honokiol to the primary cultured cerebellar neurons was initiated as our previous report . Honokiol was dissolved in ethanol and diluted sequentially in culture medium to final concentrations of 20 µM. Control group was treated with solvent alone at the same dilution as that used for drug treatment (0.1% v/v). The culture medium was completely replaced every day with fresh medium containing the appropriate drug. After treatment of honokiol, cells were harvested and treated with lysis buffer. The extracts were centrifuged at 20,000 × g for 20 min. Equal amounts of proteins were separated on a SDS 12% polyacrylamide gel, and transferred to a nitrocellulose membrane (Hyboud ECL, Amersham Pharmacia Biotech Inc., Piscataway, NJ, USA). The blots were blocked for 2 h at room temperature with 5% (w/v) nonfat dried milk in Tris-buffered saline solution (10 mM Tris, pH 8.0 and 150 mM NaCl) containing 0.05% Tween-20. The membrane was incubated with the specific rabbit polyclonal antibodies against GABA A receptor subunits or GAD65/67 (1:500), for 6 h at room temperature. The blots were then incubated with the corresponding conjugated anti-rabbit immunoglobulin G-horseradish peroxidase. The immunoreactive proteins were detected using the ECL Western blotting detection system.
Statistical Analysis
Data were presented as the mean±SEM. For the statistical comparison, the results were analyzed using analysis of variance (ANOVA). A P-value < 0.05 was considered a statistically significant difference. In case of significant variation, the individual values were compared with Dunnett's test. 
RESULTS
Effects of honokiol on pentobarbital-induced sleeping in mice
Thirty minutes after the oral administration of honokiol (0.05, 0.1, and 0.2 mg/kg), the ICR mice were received sodium pentobarbital (42 mg/kg, i.p.). The time elapsed from pentobarbital injection to the loss of the righting reflex was taken as sleeping latency. The time elapsed between the loss and voluntary recovery of the righting reflex was considered as the total sleeping time. Although all these tested three dosages of honokiol had no effect on the latency of pentobarbital-induced sleep, honokiol (0.1 and 0.2 mg/kg) increased sleeping time induced by pentobarbital from 95.6±5.7 min to 145.3 and 150.2 min, respectively, in a dose-dependent manner. (Figure 2) 
Effects of honokiol on Cl -influx in the primary cultured cerebellar neurons
Resting intracellular Cl -concentrations were calibrated using standard Cl 
Effects of honokiol on the expression of GABA A receptor subunits
Treatment of primary cultured cerebellar granule cells with 20 µM honokiol for 5 d could selectively increase the expression of GABA A receptor α-subunit ( Figure 4A ), but had no effect on the abundance of β-subunit ( Figure 4B ) or γ-subunit ( Figure 4C ).
Effects of honokiol on the expression of GAD 65/67
In order to make sure whether honokiol affects pentobarbital-induced sleeping behaviors through the synthesis of GABA, the effects of treatment to cerebellar granule cells for 5 d with 20 µM honokiol on the expression of GAD65/67 was detected. Chronic treatment of honokiol showed no effect on the abundance of GAD. (Figure 5) 
DISCUSSION
In the present study, we have demonstrated that honokiol, a biophenolic component isolated from Magnolia officinalis, potentiated pentobarbital-induce sleeping behaviors. The increase and decrease in pentobarbital-induced sleep time can be a useful tool for examining investing influences on the GABAergic systems (Liao et al., 1998) . Pentobarbital is known to potentiate the effects of GABA, acting at GABA receptors ionophore complex (Olsen, 1981; Ticku and Maksay, 1983) . Many hypnotic, anti-anxiety and anti-epilepsy drugs have prolonged pentobarbital-induced sleeping time. Our results showed that honokiol potentiated pentobarbital-induce sleeping time in mice at the dosage of 0.1 and 0.2 mg/kg, but did not change the sleeping latency. This is in agreement with those described for an extract of Magnolia obovata, in which honokiol is thought to be a major effective component (Martínez et al., 2006) . Recent evidence indicated that honokiol possessed the neuroprotective eects, and some of these studies suggest that the amelioration of neurotoxicity by honokiol may be attributed to the anti-oxidative and anti-inammatory actions through, at least in part, limiting lipid peroxidation and reducing neutrophil activation/inltration during ischemia and heatstroke (Sheu et al., 2008; Fukuyama et al., 2002) . Laboratory studies also revealed that a partially reduced derivative of honokiol, dihydrohonokiol-B (DHH-B; 3'-(2 propenyl)-5-propyl-(1,1'-biphenyl)-2,4'-diol), was also an effective anxiolytic-like agent in mice (Maruyama et al., 2001) . Another possible mechanism for honokiol-mediated neuroprotective effects is thought blockade of glutamate and N-methyl-D-aspartic acid (NMDA) activated excitotoxicity and disruption of ionic homeostasis on various CNS injuries (Lin et al., 2005) . However, GABA, as a major inhibitory amino acid transmitter in CNS, must involves in the counterpoise between excitatory and inhibitory regulation in CNS. Bath application of GABA or GABA A receptor agonist muscimol could induce an early hyperpolarization mediated by Cl -and a late depolarization mediated by the efflux of bicarbonate. These GABA A receptor-mediated responses were blocked by Cl -channel blocker picrotoxin and GABA A receptor blocker bicuculline (Xie et al., 2006) , picrotoxin and bicuculline could also induce seizure or convulsion (Cz³onkowska et al., 2000; Yamada et al., 2001) . Recent investigation revealed that picrotoxin and bicuculline significantly antagonized the melatonin-induced increase in total sleep time, slow-wave sleep and paradoxical sleep, and the decrease in time to sleep onset and wakefulness (Wang et al., 2003) . There are reports about the synergistic effect of honokiol with muscimol (a standard agonist of GABA A receptors) interacting with GABA A receptors in vitro (Squires et al., 1999; Ai et al., 2001) . Therefore, we demonstrate that prolongation of sleeping by honokiol may be due to an effect on the CNS via the GABAergic systems.
GABA A receptors are the major members of the ligandgated ion-channel families and the primary means for exerting inhibitory control throughout the central and peripheral nervous systems. And they are also the target for a wide range of therapeutic agents such as benzodiazepines, barbiturates, and anesthetics. Barbiturates, such as pentobarbital, have three distinct effects on GABA A receptor activity. To investigate the detailed mechanisms involved in the prolongation to the pentobarbital-induced sleeping time caused by honokiol, the effect of honokiol on the Cl -influx in primary cultured cerebellar neurons was evaluated. Our results showed that honokiol (20 and 50 µM) increased the influx of Cl -in primary cultured cerebellar granule cells, and pentobarbital (10 µM) also increased the intracellular concentration of Cl -in primary cultured cerebellar granule cells. The results indicate that honokiol has a similar act of pentobarbital on the GABA-gated Cl -channel. So, it is proposed that honokiol might act on functions of GABA receptors to induce Cl -channel opening, and modulate pentobarbital-induced pharmacological properties like a GABA receptor agonist.
Therefore, we tried to find out the typical responding subunits of the effective dosages of honokiol, which might have at least a close relationship with the acting site by which honokiol acts on GABA A receptors and exerts its sleeping potentiating effects. Our results showed that chronic treatment of primary cultured cerebellar granule cells with 20 µM honokiol increased the GABA A receptor α-subunit expression, but had no effect on the abundance of β or γ-subunits. To date, a great deal is known about the molecular composition of these receptors and how the distinct subtypes are constructed to form the characteristic pentameric channel-protein complex with a central chloride-selective pore (Sieghart and Sperk, 2002; Mckernan and Whiting, 1996; Chebib and Johnston, 2000) . These receptor subtypes have discrete distributions in the brain, suggesting that they fulll different functional roles (Pirker et al., 2000) . Expression studies of different subunit combinations have clearly defined some of the pharmacological differences between specific receptor combinations that are thought to be expressed in vivo (Korpi et al., 2002) . It has been confirmed that removal of either α 1 or β 2 subunits of GABA A receptors are produced strongly and selective decreases in hypnotic effects of different drugs (Blednov et al., 2003) . We also investigated the effects of honokiol on the expression of GAD65/67. GAD65/67, which is necessary for GABA synthesis, plays a major role in GABA transmission in normal physiological condition. In this study, chronic treatment of honokiol showed no effect on the abundance of GAD65/67.
In conclusion, all the data presented here indicate that honokiol can enhance hypnotic effects of pentobarbital. The GABA A receptor/chloride channel complex might be involved in the mechanisms of these actions. Further investigation is needed in order to understand the pharmacological characteristics of honokiol.
